Compare · PCRX vs PYPD
PCRX vs PYPD
Side-by-side comparison of Pacira BioSciences Inc. (PCRX) and PolyPid Ltd. (PYPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. PCRX focuses on Biotechnology: Pharmaceutical Preparations, while PYPD focuses on Medical/Dental Instruments.
- PCRX is the larger of the two at $1.46B, about 10.9x PYPD ($134.1M).
- PCRX has been more active in the news (8 items in the past 4 weeks vs 7 for PYPD).
- PCRX has more recent analyst coverage (25 ratings vs 7 for PYPD).
- Company
- Pacira BioSciences Inc.
- PolyPid Ltd.
- Price
- -
- -
- Market cap
- $1.46B
- $134.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2011
- 2020
- News (4w)
- 8
- 7
- Recent ratings
- 25
- 7
Pacira BioSciences Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.
PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Latest PCRX
- Ingram Micro Holding Set to Join S&P SmallCap 600
- SEC Form 10-Q filed by Pacira BioSciences Inc.
- Pacira BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Viatris Reports Third-Quarter 2026 Financial Results
- Chief Financial Officer Cross Shawn covered exercise/tax liability with 9,540 shares, decreasing direct ownership by 9% to 95,801 units (SEC Form 4) (tax liability)
- Amendment: SEC Form SC 14D9/A filed by Pacira BioSciences Inc.
- Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
- SEC Form SC 14D9 filed by Pacira BioSciences Inc.
- Senior Vice President, Finance Riker Lauren sold $217,920 worth of shares (6,000 units at $36.32) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SC14D9C filed by Pacira BioSciences Inc.
Latest PYPD
- SEC Form 6-K filed by PolyPid Ltd.
- PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
- SEC Form 6-K filed by PolyPid Ltd.
- PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
- Oppenheimer initiated coverage on PolyPid Ltd. with a new price target
- PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
- PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
- SEC Form 6-K filed by PolyPid Ltd.
- European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀